Board of Directors

Richard Chyette, Corporate Counsel/Secretary, Quicken Loans Inc.; Advisor, Camelot Ventures LLC
Rick Rathmann, Chairman
Ram Mandalam, President & CEO
Steve Greenberg, Managing Director, Allen & Company LLC
Antoun Nabhan, Principal, Sagamore Bioventures
George B. Rathmann, Chariman Emeritus

Richard Chyette is Corporate Counsel and Corporate Secretary to Quicken Loans Inc., the nation's largest on-line residential mortgage lender and the 15th largest retail mortgage lender overall. He has been a member of the company's senior leadership team since 1993 and is an officer of the company's holding company, Rock Holdings Inc. Mr. Chyette holds a law degree from Wayne State University and a Masters degree in Labor and Industrial Relations from Michigan State University, where he also completed his undergraduate studies. Mr. Chyette is an advisor to Daniel Gilbert (the founder and current chairman of Quicken Loans who is also a majority owner of the Cleveland Cavaliers) with respect to various business ventures and real estate transactions, and is an advisor to Camelot Ventures, a venture capital firm headed by Mr. Gilbert.

Richard G. Rathmann, Chairman, is the Managing Member of GBR Investments, LLC, (the private investment fund of George B. Rathmann, cofounder of Amgen, ICOS) and the Executive Director of the Rathmann Family Foundation. From 1994 to 1998, Mr. Rathmann co-managed the seed and early stage venture fund Falcon Technology Partners, L.P. (Adolor, Caliper, Ceptyr, Ciphergen, Decode, Genomica). Mr. Rathmann received his B.A. from the University of Colorado and his J.D. degree from Boston College Law School. A former Assistant United States Attorney in the Central District of California (Los Angeles), Mr. Rathmann now serves on the Board of Directors of NaniRx Inc., the Rathmann Family Foundation, Cellerant Therapeutics, and the National Science and Technology Medals Foundation.

Ram Mandalam, Ph.D., our President & CEO, joined the company in 2005. Ram was previously Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. Prior to Geron, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.

Steve Greenberg has been a managing director of Allen & Company LLC since January 2002. At Allen & Company, he is part of the firm’s investment banking group. Immediately prior to joining Allen & Company, Mr. Greenberg was the Co-founder and Chairman of Fusient Media Ventures, a New York-based sports and media company. Prior to starting Fusient, Mr. Greenberg co-founded Classic Sports Network in 1993 and served as its president until the network was sold to ESPN in 1997. From 1990 to 1993, Mr. Greenberg served as the Deputy Commissioner and Chief Operating Officer of Major League Baseball under Commissioner. At MLB, Mr. Greenberg oversaw the day-to-day operations of the Commissioner’s office, including Broadcasting, Finance, Legal, Baseball Operations, Special Events and the League’s lucrative properties licensing operation. Prior to MLB, Mr. Greenberg practiced law from 1977 through the end of 1989 with the Los Angeles firm of Manatt, Phelps & Phillips where he specialized in Sports and General Business Law and served as the firm’s managing partner in 1987 and 1988. Mr. Greenberg earned his B.A. at Yale University in 1970 and subsequently received his J.D. degree from the UCLA Law School in 1977. Mr. Greenberg currently serves on the Board of Directors of The Topps Company (Nasdaq – TOPP) and Convera Corporation (Nasdaq – CNVR).

Antoun Nabhan is a Principal with Sagamore Bioventures (formerly Novel Bioventures), a venture fund focused on investments in biotechnology and the life sciences. Mr. Nabhan was VP of Finance and Business Development at Incellico, Inc., a systems biology company he co-founded, which was acquired by Genstruct, Inc. He previously served at the Venture Law Group (now Heller Ehrman) and Deloitte Consulting. Mr. Nabhan graduated Phi Beta Kappa from the University of Chicago and received his J.D. from Harvard Law School, where he was an Affiliate of the Harvard Center on Law and Technology.

George B. Rathmann, Ph.D., Chairman Emeritus, received his B.S. in Physical Chemistry from Northwestern University, and his Ph.D. in Physical Chemistry from Princeton University. Dr. Rathmann was a founder of ICOS Corporation and served as Chairman of the Board from 1990 until January 2000. While at ICOS, he also served as Chief Executive Officer and President, from September 1991 until June 1999. Prior to ICOS, Dr. Rathmann co-founded Amgen, Inc. in 1980, where he served as a Director until 1993. At Amgen, Dr. Rathmann also served as Chairman of the Board, Chief Executive Officer and President at various times. Since 1982, he has served as an Officer and Board Member of the Biotechnology Industry Organization and was Chairman from 1986-1988. Dr. Rathmann is a member of the National Academy of Engineering, the American Association for the Advancement of Science and the American Chemical Society and has been the recipient of a number of awards and honors.